European private equity firm Charterhouse Capital Partners has invested in Skin Tech Pharma Group, a global medical aesthetics group headquartered in Spain.
The investment is expected to support Skin Tech’s entry into new markets, product innovation, and operational and marketing expansion through organic growth and targeted M&A.
According to a statement, Skin Tech was founded by Dr Philippe Deprez in 1996 and produces hyaluronic acid-based injectables, topical peelings, mesotherapy and cosmetic products. Its products are currently sold in over 80 countries.
Charterhouse’s previous healthcare investments include Cooper, an over-the-counter drug manufacturer and distributor; SERB Pharmaceuticals, a specialty pharmaceutical group; and most recently Labomar, a dietary supplements, medical devices and cosmetics manufacturer.
